Investors St. Louis Arch Angels, BioGenerator Ventures and Missouri Technology Corporation support MaxFi’s disruptive technology revolutionizing medical training with lifelike cadaver simulations

Maximum Fidelity Surgical Simulations (MaxFi), which provides lifelike cadavers to create highly realistic surgical simulations for medical education, research and product development, and military training, has completed its seed funding round. Led by investors St. Louis Arch Angels, BioGenerator Ventures and Missouri Technology Corporation (MTC), the initial seed funding round raised $2.25 million.

“The learning experiences MaxFi provides that empower medical professionals to optimize patient outcomes and inventors to innovate safely and efficiently drove our decision to invest,” said St. Louis Arch Angels President Brian Kinman. “We are confident MaxFi will grow into a substantial business that will advance St. Louis’ reputation as a leader in healthcare.”

“BioGenerator invested in MaxFi because we believe their unique surgical simulation services have demonstrated strong market demand, bolstered by a proven leadership team and a clearly articulated operational plan,” said BioGenerator Managing Director Crystal Winkeler.

“MTC is excited to add MaxFi to our IDEA Fund portfolio after closing an investment in the company from our IDEA Fund through the Seed Capital Program,” said MTC Executive Director Jack Scatizzi. “MTC is committed to supporting early-stage high-growth potential companies with equity-based funding through our state-sponsored venture capital program in alignment with our mission of catalyzing innovation and entrepreneurship for an economic development impact in Missouri.”

Founded by Joss Fernandez, MD, FACS in 2014 in Columbia, Missouri, MaxFi is revolutionizing surgical simulation with its patented and proprietary cadaver perfusion system that makes cadavers bleed, breathe and handle like live patients. Healthcare professionals and military medical personnel rely on MaxFi surgical simulations to gain realistic operating room and trauma care experience. Medical device manufacturers also partner with MaxFi to safely and cost effectively conduct research and test new products in a lifelike environment. Current customers include Johnson & Johnson, Washington University in St. Louis, and Safeguard Medical.

“The completion of this seed funding round is a significant milestone that validates our efforts and vision and marks a crucial step toward commercialization,” Dr. Fernandez said. “We believe we have developed a viable, sustainable and accurate solution to meet the pressing need for realistic training for physicians, military personnel and medical device developers.”

The capital raised will be used to build a leading-edge medical device development and surgical simulation center in St. Louis. Equipped with state-of-the-art labs, meeting spaces, lecture rooms and more, the center will be the only one in the world focused on providing lifelike cadavers to ensure clients experience the most realistic surgical scenarios. The funds will also support the addition of full-time employees, the development and launch of new technology, and expansion to new markets.

“We are grateful for our investors, who are enabling us to meet the increasing demand for our simulations and scale our operations to new heights,” said MaxFi CEO Bob Mills. “Most importantly, they are supporting our efforts to make discoveries that save lives and move the practice of medicine forward.”

About Maximum Fidelity Surgical Simulations

Maximum Fidelity Surgical Simulations (MaxFi) is revolutionizing surgical simulation by offering perfused cadavers that deliver unparalleled realism, precisely simulating physiological conditions such as heartbeat, blood pressure and the ability to replicate bleeding and clotting scenarios. MaxFi's technology ensures a highly realistic experience, empowering researchers, educators and medical device companies to enhance patient care and innovate new medical devices. For more information visit max-fi.com.

Maggie Teson Common Ground Public Relations 636-530-1235, ext. 223 maggiet@commongroundpr.com